How Much Does Dayvigo (Lemborexant) Cost in Missouri in 2026?

Missouri Retail Pharmacy Pricing for Dayvigo

The gap between list price and what you actually pay at a Missouri pharmacy is significant. Eisai sets Dayvigo's wholesale acquisition cost at $320 for a 30-day supply, but competitive pharmacy pricing and discount programs compress the real out-of-pocket number. Across Missouri retail pharmacies in 2026, average cash-pay pricing lands near $85 per month for both the 5 mg and 10 mg strengths.

Prices vary by pharmacy and region. Rural Missouri pharmacies may price slightly higher due to lower prescription volume, while pharmacies in the St. Louis and Kansas City metro areas tend to cluster near or below the state average. Warehouse clubs like Costco and Sam's Club often post the lowest cash prices, sometimes dipping below $75 per month even without membership-based discount programs.

GoodRx, RxSaver, and similar aggregator platforms can push prices lower still. These tools negotiate pre-set rates with pharmacy benefit managers and pass the savings through at checkout. A GoodRx coupon at a Missouri Walgreens or CVS typically brings Dayvigo into the $70 to $90 range for a 30-tablet supply 1. The FDA-approved label confirms both 5 mg and 10 mg tablets as available strengths, so pricing is consistent across doses.

One detail worth noting: Dayvigo has no generic equivalent as of May 2026. Eisai holds patent protection, and no abbreviated new drug application (ANDA) for lemborexant has received FDA tentative approval. This keeps cash-pay floors higher than they would be for genericized sleep medications like zolpidem, which runs $8 to $15 per month at most Missouri pharmacies.

Missouri Medicaid and MO HealthNet Coverage

Missouri Medicaid (MO HealthNet) does not cover Dayvigo for primary insomnia as of 2026. The drug appears on the state's non-preferred or excluded formulary tier for sleep-related diagnoses. Patients enrolled in MO HealthNet who need a DORA-class medication may face a coverage denial at the pharmacy counter.

There is a narrow exception. MO HealthNet has historically processed Dayvigo claims tied to type 2 diabetes (T2D) diagnoses where insomnia is documented as a comorbidity affecting glycemic control. This pathway requires the prescribing clinician to submit documentation linking the sleep disorder to metabolic outcomes. The American Academy of Sleep Medicine's 2023 clinical practice guideline notes that "insomnia treatment in patients with type 2 diabetes may improve HbA1c by reducing sleep-related sympathetic activation" 2. That clinical rationale can support a prior authorization appeal, but approval is not guaranteed.

For Missouri Medicaid enrollees denied coverage, alternatives include suvorexant (Belsomra), which sits on MO HealthNet's preferred formulary, and older agents like trazodone or doxepin at low doses. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant improvements in sleep onset latency and wake after sleep onset compared to placebo at one month 3. Patients who have tried and failed preferred agents have the strongest case for a Medicaid exception request.

Commercial Insurance Coverage in Missouri

Most major commercial insurers operating in Missouri place Dayvigo on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. This means coverage is available but typically requires prior authorization and, in many plans, step therapy documentation showing inadequate response to a first-line agent.

Blue Cross Blue Shield of Kansas City, Anthem Blue Cross (Missouri market), and UnitedHealthcare Community Plan all list Dayvigo as covered with prior authorization. Copays on Tier 3 plans generally range from $35 to $75 per month. Tier 4 copays or coinsurance can run $75 to $150.

Step therapy criteria across Missouri commercial plans commonly require documentation of one failed trial with either a Z-drug (zolpidem, eszopiclone) or a sedating antidepressant (trazodone, doxepin). Some plans also accept a documented contraindication to benzodiazepine receptor agonists as meeting step therapy requirements without a trial. The Endocrine Society's 2024 position statement emphasized that "dual orexin receptor antagonists represent a preferred pharmacologic option for patients with insomnia and concurrent metabolic risk, given their neutral-to-favorable weight profile" 4.

If your plan denies Dayvigo, request the specific denial reason in writing. Missouri insurance regulations (Mo. Rev. Stat. § 376.1224) require insurers to provide written rationale for formulary denials and outline an appeals process. A peer-to-peer review between your prescriber and the plan's medical director resolves many Dayvigo denials on first appeal.

The Eisai Savings Card and Patient Assistance

Eisai, the manufacturer of Dayvigo, operates two programs that can dramatically reduce costs for Missouri residents. The first is the Dayvigo Savings Card, available to commercially insured patients. Eligible patients may pay as little as $0 per 30-day fill, with the card covering the difference between the patient's copay and up to $400 per month.

Eligibility rules are straightforward. You must have commercial insurance (employer-sponsored, marketplace, or individual plan), carry a valid prescription for Dayvigo, and fill at a participating pharmacy. The card does not apply to prescriptions paid by Medicare, Medicaid, TRICARE, or other government-funded programs. Most Missouri chain pharmacies (CVS, Walgreens, Walmart, Hy-Vee) accept the savings card at the point of sale 1.

The second program is the Eisai Patient Assistance Program (PAP), designed for uninsured or underinsured patients. Income thresholds typically sit at or below 400% of the federal poverty level. Approved applicants receive Dayvigo at no cost, shipped directly to their prescriber's office or home address. Processing takes two to four weeks, so clinicians often bridge patients with samples during the approval window.

A practical tip: apply for the savings card first, even before filling the prescription. Missouri pharmacies can process the card retroactively for the current fill, but not for prior months. Having the card on file before the first fill avoids the common scenario of paying full copay on month one and receiving the discount starting month two.

Compounded Lemborexant in Missouri

Compounded lemborexant is available in Missouri through licensed 503A compounding pharmacies. This option exists because lemborexant is not on the FDA's "difficult to compound" list and does not appear on the current Bulk Drug Substances list maintained under section 503A of the Federal Food, Drug, and Cosmetic Act 5.

Missouri 503A pharmacies compound patient-specific prescriptions based on a valid prescriber-patient relationship. The Missouri Board of Pharmacy regulates these facilities under 20 CSR 2220, requiring current good compounding practices and routine inspections. Compounded lemborexant formulations may include custom doses not available commercially (for example, 2.5 mg or 7.5 mg) or alternative delivery forms such as sublingual troches.

Cost is the primary draw. Some Missouri 503A pharmacies offer compounded lemborexant at substantially lower prices than the branded product. Pricing varies by pharmacy, but patients have reported monthly costs ranging from $30 to $60 for compounded preparations. The trade-off: compounded drugs do not undergo the same FDA approval process as manufactured products, and bioequivalence testing is not required.

Dr. Michael Thorpy, professor of neurology at Albert Einstein College of Medicine, has stated that "compounded orexin receptor antagonists may serve patients who cannot access branded formulations, but prescribers should verify the compounding pharmacy's accreditation and testing protocols" 6. The Accreditation Commission for Health Care (ACHC) and PCAB (Pharmacy Compounding Accreditation Board) maintain directories of accredited compounding pharmacies, including Missouri facilities.

Before pursuing compounded lemborexant, confirm that your prescriber is willing to write a compound-specific prescription. Standard Dayvigo prescriptions cannot be modified by a pharmacy into compounded preparations without a new prescription specifying the compounded formulation.

Telehealth Access to Dayvigo in Missouri

Missouri permits telehealth prescribing of Dayvigo. The state's telehealth parity law (Mo. Rev. Stat. § 191.1145) requires insurers to cover telemedicine visits at the same rate as in-person visits, and prescribers licensed in Missouri can prescribe Schedule IV controlled substances (including lemborexant) via telehealth after conducting an appropriate evaluation.

This matters for cost because telehealth platforms often serve as a gateway to discount pharmacy networks. Several national telehealth insomnia services partner with mail-order pharmacies that offer Dayvigo at or below Missouri's average cash-pay price. The visit itself typically costs $50 to $100 for an initial evaluation and $30 to $50 for follow-ups when paying out of pocket.

The DEA's current telemedicine prescribing rules, extended through 2026, allow Schedule IV substances like lemborexant to be prescribed via audio-video telehealth without a prior in-person visit 7. Missouri-licensed prescribers must still document a clinical evaluation sufficient to establish a diagnosis of insomnia disorder, including screening for obstructive sleep apnea and other conditions that mimic or worsen insomnia.

Patients in rural Missouri counties without a sleep specialist benefit most from this pathway. In-person sleep medicine appointments in outstate Missouri often carry wait times of six to twelve weeks. A telehealth evaluation can typically be scheduled within days, accelerating time to treatment.

How Dayvigo Compares to Other Missouri Sleep Medication Costs

Placing Dayvigo's Missouri pricing in context helps determine whether the drug represents reasonable value. Generic zolpidem (Ambien) runs $8 to $15 per month at Missouri pharmacies. Generic suvorexant is not yet available. Branded Belsomra (suvorexant) costs approximately $350 to $400 per month at list price, though cash-pay discounts bring it closer to $90 to $120.

Lemborexant's pharmacologic advantage over Z-drugs is its mechanism. As a dual orexin receptor antagonist, it blocks the wake-promoting orexin neuropeptide system rather than broadly enhancing GABAergic inhibition. The SUNRISE-1 trial showed lemborexant 10 mg reduced subjective wake after sleep onset by 32.4 minutes versus 5.2 minutes for placebo (P<0.001) at the one-month endpoint 3. The SUNRISE-2 extension study demonstrated sustained efficacy over 12 months with no evidence of dose escalation or rebound insomnia on discontinuation 8.

For patients concerned about next-day sedation and falls (particularly adults over 65), the DORA class has a more favorable safety profile than benzodiazepine receptor agonists. The American Geriatrics Society Beers Criteria list zolpidem and other Z-drugs as potentially inappropriate in older adults, while DORAs are not included on the avoid list 9.

The cost-per-quality-adjusted outcome math shifts depending on the patient. For someone with commercial insurance and an Eisai savings card, Dayvigo at $0 to $35 per month is among the cheapest branded sleep medications available. For an uninsured patient paying $85 per month cash, the premium over generic zolpidem ($8 to $15) is real but may be justified by the clinical profile, particularly for patients over 55, those with substance use history, or those who have experienced parasomnias on Z-drugs.

Tips for Getting the Lowest Dayvigo Price in Missouri

Start with the Eisai savings card if you have commercial insurance. Apply online or through your prescriber's office before filling the first prescription. Second, compare prices across at least three Missouri pharmacies using a platform like GoodRx or RxSaver. Pharmacy-to-pharmacy variation of $20 to $40 per fill is common.

If you are uninsured, apply for the Eisai Patient Assistance Program. While the application processes, ask your prescriber about compounded lemborexant from a Missouri-licensed 503A pharmacy as a bridge. Verify the pharmacy holds PCAB or ACHC accreditation.

For Medicaid enrollees, discuss with your prescriber whether a prior authorization citing comorbid metabolic conditions is appropriate. If Dayvigo remains inaccessible, suvorexant (Belsomra) on MO HealthNet's preferred list is the closest pharmacologic alternative within the same drug class.

Mail-order pharmacies affiliated with your insurance plan often offer 90-day supplies at the cost of two copays, effectively cutting monthly cost by one-third. Ask your plan's pharmacy benefit manager whether Dayvigo is available through their mail-order channel before defaulting to retail.

Prescribers writing the initial prescription should specify "may substitute" to allow pharmacists flexibility in sourcing, though because no generic lemborexant exists, this currently has limited practical impact. It does, however, position the prescription for automatic generic substitution if and when an ANDA is approved.